Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):391-2. doi: 10.1097/00126334-200104010-00020.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects
  • HIV Protease Inhibitors / pharmacology
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • HIV-1 / physiology
  • Humans
  • Nelfinavir / administration & dosage
  • Nelfinavir / adverse effects
  • Nelfinavir / pharmacology
  • Nelfinavir / therapeutic use*
  • Oxazines / administration & dosage
  • Oxazines / adverse effects
  • Oxazines / pharmacology
  • Oxazines / therapeutic use*
  • RNA, Viral / analysis
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / pharmacology
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Spain
  • Treatment Failure
  • Viral Load*
  • Virus Replication / drug effects

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Oxazines
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Nelfinavir
  • efavirenz